Interesting facts
Interesting Facts about (6aR,9R)-N-[(1S)-1-(hydroxymethyl)propyl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
The compound (6aR,9R)-N-[(1S)-1-(hydroxymethyl)propyl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide belongs to a class of chemical compounds that exhibit fascinating structural diversity and biological significance. Below are some intriguing aspects of this compound:
- Structural Complexity: This compound features a unique bicyclic structure that integrates an indole and a quinoline framework, demonstrating the intricate nature of heterocyclic chemistry.
- Pharmaceutical Potential: Compounds like this one have been studied for their potential therapeutic applications, particularly in the fields of oncology and neurology, owing to their ability to interact with various biological targets.
- Chirality: The presence of multiple chiral centers in the molecule makes it an excellent subject for stereochemistry studies, highlighting the importance of 3D molecular orientation in biological activity.
- Hydroxymethyl Group: The hydroxymethyl substituent is known to enhance solubility and can influence the compound's interaction with biological systems, potentially improving its pharmacokinetic properties.
Overall, this compound serves as an exemplar of how small changes in molecular structure can lead to significant variations in biological activity, providing a rich field for research and exploration. As chemists delve deeper into its characteristics, they often quote, "The magic lies in the details of molecular interactions."
Synonyms
methylergonovine
Methylergometrine
Methylergobasin
Methylergometrin
Methylergobasine
Methylergobrevin
Methylergonovin
Methergen
Partergin
113-42-8
Basofortina
Ergotyl
Metilergometrina
Metilergometrinio
Methylergometrinum
Methergine
Lysergic acid butanolamide
Ergometrine, methyl-
ME 277
Methylergometrinum [INN-Latin]
Metilergometrinio [INN-Spanish]
D-Lysergic acid-(+)-butanolamide-(2)
HSDB 3364
EINECS 204-027-0
UNII-W53L6FE61V
N-(alpha-(Hydroxymethyl)propyl)-D-lysergamide
W53L6FE61V
Methylergometrine (INN)
(6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
Lysergamide, N-((S)-1-(hydroxymethyl)propyl)-
9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-6-methylergoline-8-carboxamide
9,10-Didehydro-N-(alpha-(hydroxymethyl)propyl)-6-methyl-ergoline-8-beta-carboxamide
Ergoline-8-carboxamide, 9,10-didehydro-N-(1-(hydroxymethyl)propyl)-6-methyl-, (8beta(S))-
D-lysergic acid 1-butanolamide
CHEMBL1201356
Methergin
NCGC00017258-04
Metilergometrina [DCIT]
(8beta)-N-[(2S)-1-hydroxybutan-2-yl]-6-methyl-9,10-didehydroergoline-8-carboxamide
Ergoline-8-beta-carboxamide, 9,10-didehydro-N-((S)-1-(hydroxymethyl)propyl)-6-methyl-
METHYLERGOMETRINE [INN]
DTXCID303283
Methylergometrinum (INN-Latin)
Metilergometrinio (INN-Spanish)
Methylergometrine [INN:BAN]
DTXSID1023283
DTXSID00904978
Ergotyl (TN)
D-Lysergic acid-dl-hydroxybutylamide-2
CAS-113-42-8
H8D
Spectrum_000263
Prestwick3_000374
Spectrum2_000613
Spectrum3_000502
Spectrum5_001879
Biomol-NT_000154
9,10-Didehydro-N-(1-(hydroxymethyl)-propyl)-D-lysergamide
9,10-Didehydro-N-[1-(hydroxymethyl)-propyl]-D-lysergamide
Lopac0_000794
SCHEMBL78176
BSPBio_000527
BSPBio_002023
GTPL150
KBioSS_000743
METHYLERGONOVINE [MI]
DivK1c_000357
SPBio_000546
BPBio1_000442
BPBio1_000581
METHYLERGOMETRINE [HSDB]
METHYLERGONOVINE [VANDF]
CHEBI:92607
KBio1_000357
KBio2_000743
KBio2_003311
KBio2_005879
KBio3_001523
G02AB01
NINDS_000357
UNBRKDKAWYKMIV-QWQRMKEZSA-N
METHYLERGOMETRINE [WHO-DD]
Tox21_110809
BDBM50330860
Tox21_110809_1
CCG-204878
DB00353
SDCCGSBI-0050771.P005
(8beta)-N-[(1S)-1-(hydroxymethyl)propyl]-6-methyl-9,10-didehydroergoline-8-carboxamide
IDI1_000357
NCGC00017258-03
NCGC00017258-05
NCGC00017258-06
NCGC00017258-08
NCGC00017258-12
NCGC00024646-02
NCGC00024646-03
DA-75495
SBI-0050771.P004
AB00514664
NS00023683
D08207
AB00053497_03
D-LYSERGIC ACID-D-1-HYDROXYBUTYLAMIDE-2
EN300-6481358
Q424477
ERGOMETRINE MALEATE IMPURITY D [EP IMPURITY]
BRD-K34685430-001-01-1
BRD-K34685430-050-04-2
BRD-K34685430-050-06-7
BRD-K34685430-050-11-7
BRD-K34685430-050-12-5
(4R,7R)-N-[(2S)-1-hydroxybutan-2-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(15),2,9,12(16),13-pentaene-4-carboxamide
(4R,7R)-N-[(2S)-1-hydroxybutan-2-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),2,9,12,14-pentaene-4-carboxamide
(8.BETA.)-N-((1S)-1-(HYDROXYMETHYL)PROPYL)-6-METHYL-9,10-DIDEHYDROERGOLINE-8-CARBOXAMIDE
(8BETA)-9,10-DIDEHYDRO-N-((1S)-1-(HYDROXYMETHYL)PROPYL)-6-METHYLERGOLINE-8-CARBOXAMIDE
204-027-0
ERGOLINE-8BETA-CARBOXAMIDE, 9,10-DIDEHYDRO-N-((S)-1-(HYDROXYMETHYL)PROPYL)-6-METHYL-
Solubility of (6aR,9R)-N-[(1S)-1-(hydroxymethyl)propyl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
This compound presents an interesting case in terms of solubility due to its complex molecular structure and the presence of various functional groups. Understanding its solubility characteristics can be crucial for applications in pharmacology and material science. Here are some key points regarding its solubility:
In conclusion, while the intricate balance between hydrophilic and hydrophobic forces will determine the overall solubility of this compound, empirical testing in various solvents will be essential to elucidate its solubility behavior comprehensively.